KLK3 and prostate cancer: Importantly, the statistical analyses were conducted post hoc and were not powered to determine statistical significance between therapies; in addition to the degarelix-treated patient group being small (n = 101), the stage of prostate cancer was unknown, PSA and testosterone levels were not available post-treatment, and data were from the OPCRD database; therefore, these findings may not be directly transferable to secondary care.